Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2014
At a glance
- Drugs EMD 640744 (Primary) ; Dendritic cell vaccines; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics
- 20 Jan 2014 This trial is expected to start in the first half of 2014, according to a Immunovaccine media release.
- 04 Jun 2013 New trial record
- 30 May 2013 This trial is expected to start in quarter 4 of 2013, to recruit at least 50 patients, and to provide initial data during the second half of 2014, according to an Immunovaccine Inc media release.